Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome

International Journal of Obesity - Tập 27 Số 7 - Trang 862-865 - 2003
Gerald F. Watts1, Dick C. Chan2, P. Hugh R. Barrett2, F.H. O’Neill3, G. R. Thompson3
1School of Medicine and Pharmacology, University of Western Australia, West Australian Institute for Medical Research, Royal Perth Hospital, Perth, W Australia. [email protected]
2School of Medicine and Pharmacology, University of Western Australia, West Australian Institute for Medical Research, Royal Perth Hospital, Perth
3Division of Investigative Science, Department of Metabolic Medicine, Imperial College School of Medicine, University of London, UK

Tóm tắt

Từ khóa


Tài liệu tham khảo

Ginsberg HN . Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453–458.

Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PHR . Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 2002; 51: 1041–1046.

Thompson GR, Naoumova R, Watts GF . Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 1996; 37: 439–447.

Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PH . Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 1999; 84:2854–2861.

Simonen PP, Gylling H, Howard AN, Miettinen TA . Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr 2000; 72: 82–88.

Miettinen TA, Tilvis RS, Kesaniemi YA . Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990; 131: 20–31.

Gylling H, Miettinen TA . Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res 1996; 37: 1776–1785.

Simonen PP, Gylling H, Miettinen TA . Body weight modulates cholesterol metabolism in non-insulin dependent type 2 diabetics. Obes Res 2002; 10: 328–335.

Watts GF, Naoumova RP, Kelly JM, Riches FM, Croft KD, Thompson GR . Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 1997; 273: 462–470.

Watts GF, Cummings MH, Umpleby M, Quiney JR, Naoumova R, Thompson GR . Sonksen PH. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur J Clin Invest 1995; 25: 559–567.

Lindenthal B, Sudhop T, Schiedermaier P, Agnan M, Sauerbruch T, von Bergmann K . Serum plant sterols and biliary cholesterol secretion in humans: studies with ursodeoxycholic acid. J Lipid Res 2002; 43: 1072–1077.

Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, Gebhard RL . Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988; 8:1147–1150.

Vanhanen H, Kesäniemi YA, Miettinen TA . Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids and cholesterol absorption in man. Metabolism 1992; 41: 588–595.

Duane WC . Effects of lovastatin and dietary cholesterol on sterol homeostasis in healthy human subjects. J Clin Invest 1993; 92: 911–918.

Sehayek E, Ono JG, Shefer S, Nguyen LB, Wang N, Batta AK, Salen G, Smith JD, Tall AR, Breslow JL . Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sci 1998; 95: 10194–10199.

Ostlund RE, Bosner MS, Stenson WF . Cholesterol absorption efficiency declines at moderate dietary doses in normal human subjects. J Lipid Res 1999; 40: 1453–1458.

Kesaniemi YA, Grundy SM . Overproduction of low density lipoproteins associated with coronary heart disease. Arteriosclerosis 1983; 3: 40–46.

Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres JP . Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955–1961.

Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, Lebeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, Veltri EP, Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001; 23: 1209–1230.

Berge KE, von Bergmann K, Lutjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC . Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J Lipid Res 2002 43: 486–494.